MARKET

XLRN

XLRN

Acceleron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.90
-2.30
-4.98%
After Hours: 43.90 0 0.00% 16:32 09/13 EDT
OPEN
46.37
PREV CLOSE
46.20
HIGH
46.37
LOW
43.80
VOLUME
396.46K
TURNOVER
--
52 WEEK HIGH
59.59
52 WEEK LOW
37.01
MARKET CAP
2.32B
P/E (TTM)
-17.8173
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XLRN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

XLRN News

  • Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus
  • Zacks.4d ago
  • FDA Grants Orphan Drug Status to Acceleron's PAH Candidate
  • Zacks.4d ago
  • Acceleron's Pulmonary Arterial Hypertension Asset Receives Orphan Drug Designation
  • Benzinga.6d ago
  • Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension
  • Benzinga.6d ago

More

Industry

Biotechnology & Medical Research
+0.20%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Name
Price
%Change

About XLRN

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.
More

Webull offers Acceleron Pharma Inc (XLRN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.